Markets & Finance

Corinthian Enrolled in S&P Top 10


On July 25, Standard & Poor's equity research group made changes to the S&P Top 10 portfolio -- those issues it considers to be the best candidates for capital gains over the next 6 to 12 months. S&P replaced pharmaceutical giant Pfizer (PFE) with fast-growing, for-profit education outfit Corinthian Colleges (COCO).

Pfizer exited the portfolio after S&P analyst Herman Saftlas downgraded the stock's investment ranking to 4 STARS (accumulate) from 5 STARS (strong buy) on July 25. (All the stocks in the portfolio are ranked 5 STARS.) The downgrade reflected Saftlas' concerns about "macro-regulatory issues" -- drug re-importation and Medicare reimbursement -- along with slowing trends in the statin market, and generic challenges to several key Pfizer drugs.

As for Corinthian, S&P analyst Michael Jaffe notes that the company is benefiting from strong student enrollment at new and existing campuses. Jaffe believes strong top-line growth and

productivity gains will fuel significant earnings per share growth for the foreseeable future. His 12-month target price for Corinthian is $65, derived by applying a 1.5 p-e-to-growth

ratio to S&P's fiscal 2004 EPS estimate of $1.80.

Year-to-date through June 30, the S&P Top Ten portfolio gained 13.69% vs. an advance of 11.76% for its benchmark, the S&P 500-stock index (both of these performances include dividends).

Here's the latest list:

S&P Top 10 Portfolio

Company

Current Price

(7/30/03 close)

12-Month Target

Investment Rationale

Boston Scientific (BSX)

63.60

70

Explosive growth prospects

Comcast (CMCSA)

30.82

37

Increasing synergies from broadband acquisition

Compass Bancshares (CBSS)

34.20

41

Valuation, positive fundamental trends

Corinthian Colleges(COCO)

54.71

65

See extended growth period; undervalued

DR Horton (DHI)

28.61

38

Better-than-expected industry trends

Fair Isaac (FIC)

58.85

68

Attractive valuation

Flextronics (FLEX)

11.52

15

Firming business, low valuation

Intel (INTC)

24.49

32

Recovery in worldwide chip demand expected to drive growth

Jacobs Engineering (JEC)

44.15

48

See strong bookings from refining customers

Martek Biosciences(MATK)

49.76

59

Annual revenue growth of nearly 100% seen through fiscal 2004

For more information about the Top 10 portfolio, please visit http://www.businessweek.com/investor/content/jun2002/pi20020617_8998.htm By Ken Shea and Robert Gold


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus